 BioSig Technologies Inc drew an Outperform rating from Noble Capital, which noted that stronger commercialization efforts are underway for the companys PURE Precise Uninterrupted Real-time evaluation of Electrograms EP systems after the first quarter. In a note to clients, Noble Capital analysts observed that BioSig recorded no PURE EP unit sales during the quarter, which was below our expectations of three units. 